LYNPARZA® Reduced Risk of Death by 32% in Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer in Phase 3 OlympiA Trial Life Science Investing
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
BetterLife Obtains In Vivo PK Data for BETR-001 Confirming its Bioavailability in Brain Pharmaceutical Investing
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm Pharmaceutical Investing
Now Available Over the Counter, LASTACAFT® Provides Eye Allergy Itch Relief in Minutes that Lasts Through 16 Hours Pharmaceutical Investing
AbbVie and Scripps Research Announce Collaboration to Develop Antiviral Treatments for COVID-19 Pharmaceutical Investing
Numinus to Participate in Maxim's 2022 Virtual Growth Conference on March 28-30, 2022 Pharmaceutical Investing
Merck Announces KEYLYNK-010 Trial Evaluating KEYTRUDA® in Combination with LYNPARZA® in Patients with Metastatic Castration-Resistant Prostate Cancer to Stop for Futility Life Science Investing
Seegnal Inc. Establishes Strategic Commercialization Team and Appoints Arx as Investor Relations Advisor
